Bioheart

Bioheart is committed to advancing the field of regenerative medicine by providing the highest quality technology, cell therapy, and training. Bioheart focuses on biotechnology, specializing in the discovery, development, and commercialization of autologous cell therapies for treating various degenerative diseases. Bioheart aims to maintain its leading position in the cardiovascular sector of the cell technology industry by offering stem cell therapies and biologics that help address congestive heart failure, critical limb ischemia, chronic cardiac ischemia, acute myocardial infarction, and both chronic and acute heart conditions. Bioheart’s goal is to improve patients' quality of life through the regeneration of damaged tissues whenever possible, while reducing healthcare costs and hospitalizations. Bioheart's key product, MyoCell, is a clinical muscle-derived cell therapy designed to populate scar tissue areas in a patient’s heart with new, living cells to enhance cardiac function in individuals with chronic heart failure.